The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of multiple oral administration of KUX-1151 in patients with hyperuricemia including gout.

开始日期-

申办/合作机构

Kissei Pharmaceutical Co., Ltd.

100 项与 KUX-1151 相关的临床结果

登录后查看更多信息

100 项与 KUX-1151 相关的转化医学

登录后查看更多信息

100 项与 KUX-1151 相关的专利（医药）

登录后查看更多信息

项与 KUX-1151 相关的文献（医药）

2018-07-03·Expert Opinion on Emerging Drugs

Expert opinion on emerging urate-lowering therapies

Review

作者: Merriman, Tony R ; Stamp, Lisa K ; Singh, Jasvinder A

INTRODUCTIONThere has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editorial summarizes new, emerging therapies for people with gout. Areas covered: We review several new therapies for gout, including those that are focused on lowering serum urate (levotofisopam, ulodesine, verinurad, merbarone, KUX-1151, UR-1102, FYU-981, SEL-212), or treating gout flares (canakinumab, bucillamine) or both (arhalofenate, diacerein). Expert opinion: Among therapies with both urate lowering and anti-inflammatory action, arhalofenate seems promising, but more data are needed. Examining therapies aimed at treating gout flares [anti-inflammatory action], bucillamine has some potential, but more data and Phase III studies are needed, to better understand its efficacy and safety. Among the urate-lowering therapies (ULTs), verinurad seems to be the most promising, while levotofisopam and ulodesine require more data. A uricase-replacement therapy with improved immune reaction (SLE-212) is in a Phase II trial. A number of ULTs including KUX-1151, UR-1102 and FYU-981 are in early development and more will be known once initial data and studies are published.

2018-05-04·Expert Opinion on Investigational Drugs2区 · 医学

Investigational drugs for hyperuricemia, an update on recent developments

2区 · 医学

Review

作者: Pascart, Tristan ; Richette, Pascal

INTRODUCTIONThe significant proportion of gout patients not reaching serum urate levels below 6.0 mg/dL and the debated pathogenicity of hyperuricemia (HU) itself motivate investigators to develop new drugs to decrease uricemia.AREAS COVEREDThis review discusses the drugs considered to be in active development from pre-clinical to phase III studies. This review covers 11 drugs in development, including a xanthine oxidase inhibitor (topiroxostat), uricosurics (verinurad, arhalofenate, UR-1102, tranilast), dual inhibitors (RLBN1001, KUX-1151), a uricase (pergsiticase), an inhibitor of hypoxanthine production (ulodesine), and drugs with yet-to-explain mechanisms of action (levotofisopam, tuna extracts).EXPERT OPINIONDrugs well advanced in their development - particularly arhalofenate, verinurad and topiroxostat - open the prospect of patient-comorbidity-tailored HU management. Development of novel therapies provides new insight into our understanding of gout and HU, particularly potential pathogenicity. Apart from potency to decrease serum urate levels and good tolerance profiles, novel therapies will need to focus on administration modalities facilitating treatment adherence.

100 项与 KUX-1151 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高尿酸血症	临床2期	日本	Kissei Pharmaceutical Co., Ltd.	2014-07-15
痛风	临床2期	日本	Kissei Pharmaceutical Co., Ltd.	-
痛风	临床2期	日本	Kissei Pharmaceutical Co., Ltd.	-
痛风	临床2期	-	Pfizer Inc.	-
痛风	临床2期	-	Pfizer Inc.	-
高钙血症	临床2期	-	Kissei Pharmaceutical Co., Ltd.	-
高钙血症	药物发现	-	Pfizer Inc.	-